Related Experiment Video
Updated: Jan 15, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Socioeconomic Status and Stroke Risk in Pediatric Sickle Cell Disease: A DISPLACE Study Secondary Analysis
Jeffrey G Edwards1, Daniel T Humphrey2, Martina Mueller2
1Department of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Insights
Hydroxyurea prescription, not socioeconomic status, significantly impacts abnormal Transcranial Doppler (TCD) results in children with sickle cell disease (SCD). This highlights the importance of HU treatment for stroke risk assessment in SCD patients.
Area of Science:
- Pediatric Hematology
- Neurology
- Public Health
Background:
- Transcranial Doppler (TCD) screening identifies stroke risk in children with sickle cell disease (SCD).
- Socioeconomic status (SES) may influence healthcare access and TCD results, but this link is not well-established.
- Previous research indicates barriers for public insurance households in low opportunity neighborhoods.
Purpose of the Study:
- To investigate the association between socioeconomic status (SES) and Transcranial Doppler (TCD) screening results in children with sickle cell disease (SCD).
- To identify factors influencing abnormal or conditional TCD results in pediatric SCD patients.
Main Methods:
- Secondary analysis of the DISPLACE study data (children aged 2-6 years).
- Utilized insurance type and Childhood Opportunity Index (COI) to represent household and neighborhood SES.
- Examined the association between SES proxies and TCD screening outcomes.
Main Results:
- The study included 3124 children; 41.5% lived in Very Low COI neighborhoods, and 64.6% had public insurance.
- Lack of hydroxyurea (HU) prescription was strongly associated with abnormal TCD results (aOR = 19.01, p < 0.001).
- Low SES proxies were not independently associated with abnormal or conditional TCD results.
Conclusions:
- Hydroxyurea (HU) prescription is the most significant factor associated with abnormal TCD outcomes in children with SCD.
- Socioeconomic status did not independently predict abnormal TCD results.
- Further qualitative research is needed to understand barriers to HU prescription in pediatric SCD care.
Background:
Transcranial doppler (TCD) screening identifies children ages 2-16 years with sickle cell disease (SCD) at an increased risk for stroke. Previous studies have shown that individuals from households on public insurance with limited neighborhood opportunity have increased barriers to receiving adequate healthcare; however, it is unknown whether low socioeconomic status (SES) influences TCD results.
Methods:
We conducted a secondary analysis of the DISPLACE study data, which included children aged 2-6 years who had at least one TCD screen performed during their year of study enrollment, if space allowed. We utilized insurance type (public insurance vs. all other insurances) and overall childhood opportunity index (COI) group (Very Low vs. all other COI levels [Low, Medium, High, and Very High]) to proxy household- and neighborhood-level SES. We then examined the association between household- and neighborhood-level SES and conditional or abnormal TCD screening results.
Results:
The analytic cohort included 3124 children, with 1295 (41.5%) children living in Very Low COI neighborhoods and 2019 (64.6%) of households with public insurance. In the multinomial logistic regression model, only the lack of HU prescription remained significantly associated at p < 0.05 with abnormal TCD result (adjusted odds ratio = 19.01, p < 0.001).
Conclusion:
Lack of hydroxyurea (HU) prescription was the factor most strongly associated with abnormal TCD outcome. Low SES proxies were not independently associated with abnormal or conditional TCD results. Qualitative studies are needed to better understand why a child with SCD might not have been prescribed HU.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

